Peptron, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Daejeon Korea, Republic of (1997)
Status: No NME R&D (1997)

Organization Overview

First Clinical Trial
2009
NCT00964262
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Peptron, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

exenatide (byetta) (2 trials)

yh14617 (1 trial)

Drugs in Phase 1 Trials (1)

leuprolide (lupron) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 1)

Parkinson Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3